150-P | COMPARATIVE ANALYSIS OF GENE REGULATORY NETWORKS IN LYMPHOID LEUKEMIAS USING THE INTERACTIVE HEMAP RESOURCE | Juha Mehtonen | Received |
152-P | HEDGEHOG PATHWAY ACTIVATION IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA PREDICTS RESPONSE TO SMO AND GLI1 INHIBITORS | Jolien De Bie | Received |
153-P | IDENTIFICATION OF CANDIDATE ONCOGENES AND CHROMOSOMAL BREAKPOINT SEQUENCING BY TARGETED LOCUS AMPLIFICATION IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | Eric Vroegindeweij | Received |
154-P | A PLATFORM FOR DETECTION OF FUSION GENES IN ALL FROM TARGET CAPTURE NEXT-GENERATION SEQUENCING OF DNA AND RNA. | Andrea Grioni | Received |
155-P | THE NUP214-ABL1 FUSION COOPERATES WITH TLX1 IN THE DEVELOPMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | Marlies Vanden | Received |
157-P | CHARACTERIZATION OF AN EX VIVO T-CELL CULTURE MODEL FOR THE STUDY OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | Simon Bornschein Bempt | Received |
160-P | DEVELOPMENT OF A NOVEL FIRST-IN-CLASS ORAL INHIBITOR OF THE NOTCH PATHWAY. | Rajwinder Lehal Bempt | Received |
162-P | LOSS OF PIGH EXPRESSION FREQUENTLY RESULTS IN A GPI-NEGATIVE SUBCLONE LACKING CD52 MEMBRANE EXPRESSION, CONFERRING ALEMTUZUMAB RESISTANCE TO B CELL ACUTE LYMPHOBLASTIC LEUKEMIA | Inge JEDEMA | Received |
164-P | BABOON ENVELOPE PSEUDOTYPED LENTIVIRAL VECTORS: A HIGHLY EFFICIENT NEW TOOL TO GENETICALLY MANIPULATE T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA INITIATING CELLS | Melania TESIO | Received |
165-P | HIGH INCIDENCE OF PHILADELPHIA CHROMOSOME-LIKE ACUTE LYMPHOBLASTIC LEUKEMIA (PH-LIKE ALL) IN OLDER ADULTS WITH B-ALL | Alexander Perl Bempt | Received |
168-P | THE COMBINATION OF BORTEZOMIB AND CHEMOTHERAPY IS AN EFFECTIVE TREATMENT TO RE-INDUCE REMISSION IN RELAPSED/REFRACTORY B-CELL PRECURSOR OR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | Alice BERTAINA Bempt | Received |
169-P | EFFICACY OF FRONT-LINE TREATMENT COMBINATIONS WITH PONATINIB VERSUS 1ST- AND 2ND-GENERATION TYROSINE KINASE INHIBITORS FOR PH+ ACUTE LYMPHOBLASTIC LEUKEMIA: A META-ANALYSIS AND META-REGRESSION | Ariadne Souroutzidis Bempt | Received |
170-P | RISK OF CEREBRAL VEIN THROMBOSIS (CVT) IN ADULT ALL PATIENTS IN FINLAND 1999-2012: SUGGESTION FOR A LEUKEMIA-RELATED PREDICTIVE SCORING MODEL | Saara Roininen | Received |
171-P | INITIAL RESULTS FROM UKALL60+, A UK/HOVON COLLABORATIVE PHASE 2 STUDY IN ELDERLY PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA. | Nick MORLEY Bempt | Received |
172-P | RELAPSE OF ACUTE LYMPHOBLASTIC LEUKAEMIA IN OLDER/ELDERLY PATIENTS - A SWEDISH POPULATION-BASED STUDY | Emma BERGFELT Bempt | Received |
173-LB | N. Toft | Received | |
174-P | VENTX INDUCES EXPANSION OF PRIMITIVE ERYTHROID CELLS AND CONTRIBUTES TO THE DEVELOPMENT OF ACUTE MYELOID LEUKEMIA IN MICE | Eva Gentner Bempt | Received |
175-P | ABNORMAL INTRAGENIC TRANSCRIPTIONAL ACTIVATION IN MLL-AF9 AND KAT6A-CREBBP ACUTE MYELOID LEUKEMIA (AML) | Anna Marneth | Received |
176-P | HHEX TRANSFORMS PROMYELOCYTES AND COOPERATES WITH FACTOR INDEPENDENCE TO CAUSE PROMYELOCYTIC LEUKEMIA IN MICE | Jacob T Jackson | Received |
177-P | A SOMATIC MUTATION OF GFI1B IDENTIFIED IN LEUKEMIA ALTERS CELL FATE VIA A SPI1 (PU.1) CENTERED GENETIC REGULATORY NETWORK | Eduardo Anguita | Received |
181-P | TRIB2 TRANSFORMED GMP AS THE MYELOID LEUKEMIA INITIATING CELL | Krishna Yalla Jackson | Received |
182-P | TRIB2 REGULATES THE CELL CYCLE UNDER STRESS CONDITIONS IN A MURINE CELL MODEL OF LEUKEMIA. | Mara Salomè Bempt | Received |
183-P | CHROMOTHRIPSIS: A NEW MECHANISM OF CANCER INITIATION AND PROGRESSION IN ADULT ACUTE MYELOID LEUKEMIA | Giovanni Martinelli Bempt | Received |
184-P | AN EVALUATION OF THE TYROSINE KINASE INHIBITOR PACRITINIB IN PATIENTS WITH RELAPSED FLT3-MUTATED ACUTE MYELOID LEUKAEMIA (THE UK NCRI AML17 STUDY) | Steven Knapper Bempt | Received |
186-P | SAFETY STUDY OF CRENOLANIB, A TYPE I FLT3 INHIBITOR, WITH CYTARABINE/DAUNORUBICIN OR CYTARABINE/IDARUBICIN INDUCTION AND HIGH-DOSE CYTARABINE CONSOLIDATION IN NEWLY DIAGNOSED FLT3+ AML | Meghan Macaraeg Bempt | Received |
187-P | PHASE II STUDY OF CLADRIBINE AND LOW-DOSE ARAC ALTERNATING WITH DECITABINE IN OLDER PATIENTS WITH AML. | Tapan Kadia | Received |
188-P | DIFFERENTIATION RESPONSE TO GILTERITINIB (ASP2215) IN RELAPSED/REFRACTORY FLT3 MUTATED ACUTE MYELOID LEUKEMIA PATIENTS IS ASSOCIATED WITH CO-MUTATIONS IN NPM1 AND DNMT3A | Jonathan Canaani Bempt | Received |
190-P | CLINICAL RESPONSE IN RELAPSED/REFRACTORY AML PATIENTS CORRELATES WITH LEUKEMIC BLAST MOBILIZATION AND DIFFERENTIATION INDUCED BY BL-8040, A POTENT CXCR4 ANTAGONIST; RESULTS OF A PHASE IIA STUDY | Yaron Pereg | Received |
193-P | A PHASE I TRIAL OF A PHARMACODYNAMICALLY-CONCEIVED DECITABINE/THIOGUANINE COMBINATION IN PATIENTS WITH ADVANCED MYELOID MALIGNANCIES | Mark Frattini Bempt | Received |
194-P | GENOMIC CHARACTERIZATION OF HIGH-COUNT MBL INDIVIDUALS INDICATES THAT EARLY DETECTION OF DRIVER MUTATIONS AND SUBCLONAL EXPANSION ARE PREDICTORS OF ADVERSE CLINICAL OUTCOME | Santiago Barrio | Received |
195-P | IDENTIFICATION OF NOVEL B CELL RECEPTOR ANTIGENS IN CHRONIC LYMPHOCYTIC LEUKEMIA | Elisa ten | Received |
198-P | IN VIVO CHARACTERIZATION OF LYN KINASE IN THE PATHOGENESIS OF CHRONIC LYMPHOCYTIC LEUKEMIA | Phuong-Hien Nguyen Hacken | Received |
199-P | MICROENVIRONMENTAL STROMAL CELLS TRIGGER HYPOXIA SIGNALLING IN CLL CELLS – A MECHANISM THAT PROVIDES PROTECTION FROM APOPTOSIS AND CAN BE TARGETED THERAPEUTICALLY | Daniel Mertens | Received |
200-P | IBRUTINIB INHIBITS CD20 UP-REGULATION ON CLL B CELLS MEDIATED BY THE CXCR4/SDF-1 AXIS | Gabriela Pavlasova Hacken | Received |
201-P | FUNCTIONAL IMPACT OF BONE MARROW MESENCHYMAL STROMAL CELL-DERIVED EXTRACELLULAR VESICLES ON CHRONIC LYMPHOCYTIC LEUKEMIA B-CELLS: APOPTOSIS, MIGRATION, CHEMORESISTANCE AND GENE EXPRESSION MODIFICATION | Emerence Crompot | Received |
202-P | THE T-CELL/CLL/MACROPHAGE TRIAD SHAPES A SUPPORTIVE TUMOR MICROENVIRONMENT IN CLL | Martijn van Attekum | Received |
204-P | BLOCKING ENDOTHELIN-1 SIGNALING DISRUPTS LEUKEMIC CELL HOMING AND B-CELL RECEPTOR PATHWAY IN CHRONIC LYMPHOCYTIC LEUKEMIA | Rossana MAFFEI Attekum | Received |
205-P | GENE EXPRESSION PROFILES OF PERIPHERAL BLOOD T AND NK-CELLS REVEALED DIFFERENT PATTERNS OF IMMUNE DYSFUNCTION IN CLL-LIKE MBL AND EARLY STAGE CLL | Anna Puiggros | Received |
206-P | CD49D EXPRESSION IMPACTS ON THE IBRUTINIB-INDUCED LYMPHOCYTOSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA: A ROLE OF BCR-MEDIATED INSIDE-OUT VLA-4 INTEGRIN ACTIVATION | Erika Tissino Attekum | Received |
210-P | PRELIMINARY RESULTS OF A PHASE II STUDY OF IBRUTINIB IN COMBINATION WITH FCR (IFCR) IN PREVIOUSLY UNTREATED, YOUNGER PATIENTS WITH CLL | Matthew Davids | Received |
211-P | PRESENCE OF MULTIPLE UNMUTATED IGHV REARRANGEMENTS IN CLL PATIENTS IS ASSOCIATED WITH A VERY SHORT TREATMENT–FREE SURVIVAL: RESULTS FROM 2 INDEPENDENT COHORTS | Basile Stamatopoulos | Received |
212-P | NON-CODING NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKAEMIA; THEIR CLINICAL IMPACT IN THE CLL4 CLINICAL TRIAL | Marta Larrayoz Attekum | Received |
213-P | UPDATED RESULTS OF A PHASE 3 RANDOMIZED, CONTROLLED STUDY OF IDELALISIB IN COMBINATION WITH OFATUMUMAB FOR PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) | Timothy Dichiara Attekum | Received |
218-P | ULTRA DEEP TARGETED NEXT GENERATION SEQUENCING FOR THE DETECTION OF SUBCLONAL TP53 ABERRATIONS IN CLL | Christian Brieghel Attekum | Received |
219-P | COMPARABLE OUTCOMES IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH REDUCED DOSE IBRUTINIB: RESULTS FROM A MULTI-CENTER STUDY | Rahul Banerjee Attekum | Received |
221-P | PATIENTS WITH COMPLEX KARYOTYPE (CK) LACKING TP53 DELETIONS SHOW AN EQUIVALENT DISMAL CLINICAL OUTCOME AS THOSE WITH TP53 DELETIONS AND NON-CK IN CHRONIC LYMPHOCYTIC LEUKEMIA | Anna Puiggros Attekum | Received |
230-P | IMPACT OF SECOND DECLINE RATE OF BCR-ABL1 TRANSCRIPT BETWEEN M3 AND M6 ON CLINICAL OUTCOME FOR CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH IMATINIB: PRACTICAL ASPECT FOR THE TRUE LIFE | Stephanie DULUCQ Attekum | Received |
232-P | LATE RELAPSES, UP TO 45 MONTHS AFTER IMATINIB DISCONTINUATION: RESULTS FROM THE ISAV STUDY | Silvia Mori Attekum | Received |
233-P | ASSESSMENT OF THERAPY RESPONSE IN CHRONIC MYELOID LEUKEMIA VIA 1 MONTH BCR-ABL1 TRANSCRIPT DECLINE | Mohamed El Missiry | Received |
234-P | DEVELOPMENT AND EVALUATION OF A MR1 – MR4.5 SECONDARY LYOPHILIZED CELL REFERENCE PANEL FOR BCR-ABL1 QUANTIFICATION ON THE INTERNATIONAL SCALE | Connie Wong Missiry | Received |
235-P | TYROSINE KINASE INHIBITORS DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS OF 208 ITALIAN PATIENTS | Carmen FAVA | Received |
236-P | MANAGING CHILDREN AND ADOLESCENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH HIGH-DOSE IMATINIB. THE ITALIAN EXPERIENCE. | Fiorina Giona Attekum | Received |
238-P | VITAMIN C INCREASES VIRAL MIMICRY INDUCED BY 5-AZA-2-DEOXYCYTIDINE | Andreas Due Ørskov | Received |
239-P | GENETIC PREDISPOSITIONS TO SPORADIC MYELOID NEOPLASMS CAUSED BY GERMLINE DDX41 MUTATIONS IN ASIAN AND CAUCASIAN POPULATIONS. | June Takeda Ørskov | Received |
240-P | IDENTIFICATION OF ALTERED AND CRYPTIC-SPLICING IN SF3B1 MUTANT MYELODYSPLASTIC SYNDROMES AND ISOGENIC MODELS OF SF3B1-K700E MUTATION | Fabio Liberante | Received |
241-P | IMPACT OF SOMATIC MUTATIONS ON OUTCOME IN PATIENTS WITH MDS AFTER STEM-CELL TRANSPLANTATION | Tetsuichi Yoshizato | Received |
242-P | 17P DELETIONS AND TP53 MUTATIONS IN PATIENTS WITH MDS/AML AND COMPLEX ABERRANT KARYOTYPE | Roxana Schaab Ørskov | Received |
243-P | TP53 AND EZH2 MUTATIONS PREDICT POOR SURVIVAL IN PATIENTS TREATED WITH HYPOMETHYLATING AGENTS IN MDS | M Teresa Cedena | Received |
244-P | AZACYTIDINE RESTORES THE ABNORMAL STAT SIGNALING BIOSIGNATURE OF FOXP3+ T REGULATORY CELLS (TREGS) IN RESPONDING MDS PATIENTS. | Ioannis KOTSIANIDIS | Received |
245-P | A CULTURE MODEL MIMICKING THE BM-NICHE ALLOWS FOR STUDYING THE DYSREGULATED ERYTHROPOIESIS OF SF3B1 MUTATED MYELODYSPLASTIC SYNDROME WITH RINGED SIDEROBLASTS | Edda María Elvarsdóttir | Received |
246-P | THE INCIDENCE AND CLINICAL IMPLICATIONS OF CHROMOTHRIPSIS IN BONE MARROW CELLS OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) | Zuzana Zemanova | Received |
247-P | MODEST EPIGENETIC EFFECT OF AZACITIDINE IN GENOME-WIDE MAPPING OF DNA METHYLATION, H3K9ME3, H3K18AC AND GENE EXPRESSION IN MDS PROGENITORS. | Magnus Tobiasson Elvarsdóttir | Received |
248-P | RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING EPOETIN ALFA VERSUS PLACEBO IN ANEMIC PATIENTS WITH IPSS LOW- INT1 RISK MDS | Wayne Elwood | Received |
250-P | MUTATIONS OF COHESIN COMPLEX GENES IN MYELODYSPLASTIC SYNDROME: DISTINCT CLINIC-BIOLOGICAL FEATURES AND PROGNOSTIC RELEVANCE | Lo-Ho Chen Elvarsdóttir | Received |
252-P | CLINICAL BENEFIT AMONG LENALIDOMIDE (LEN)-TREATED PATIENTS (PTS) WITH RBC TRANSFUSION-DEPENDENT (RBC-TD) LOW-/INT-1-RISK MYELODYSPLASTIC SYNDROMES (MDS) WITHOUT DEL(5Q) | Guillermo Garcia-Manero Elvarsdóttir | Received |
254-P | THE USE OF A HIGH DENSITY, 2.6 MILLION MARKER, SNP ARRAY AS THE PRIMARY GENETIC TEST FOR MYELODYSPLASTIC SYNDROME AT DIAGNOSIS: INTERIM FINDINGS OF THE WEST MIDLANDS, UK STUDY | Nicola Trim Elvarsdóttir | Received |
257-P | FREQUENT MUTATIONS IN EPIGENETIC REGULATORS IN CYTOPENIA OF UNDETERMINED SIGNIFICANCE: ASSOCIATION WITH RISK OF PROGRESSION TO MYELODYSPLASTIC SYNDROME | Jakob Werner Hansen | Received |
258-P | MOLECULAR AND CLINICAL TYPES OF PLASMA CELL DYSCRASIAS ARE ASSOCIATED WITH DISTINCT EXPRESSION PATTERNS OF LONG NONCODING RNAS | Martina Manzoni Hansen | Received |
259-P | RPL5 ON 1P22 IS RECURRENTLY DELETED IN MULTIPLE MYELOMA AND ITS EXPRESSION IS LINKED TO BORTEZOMIB RESPONSE | Isabel Hofman Hansen | Received |
260-P | COMPREHENSIVE CHARACTERIZATION OF THE GENOMIC LANDSCAPE OF MULTIPLE MYELOMA WITH A DELETION OF CHROMOSOME 17P REVEALS A HIGH PREVALENCE OF SOMATIC TP53 MUTATIONS, WHICH CORRELATE WITH A POOR PROGNOSIS | Davine Hofste op | Received |
261-P | DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY | Nicola GIULIANI | Received |
262-P | LOSS OF PRIMING OR MCL-1 DEPENDENCY CONFERRED ACQUIRED RESISTANCE TO VENETOCLAX IN MULTIPLE MYELOMA | Martine Amiot op | Received |
263-P | LOSS OF THE INHIBITORY RECEPTOR CD85J/LILRB1 ON MALIGNANT PLASMA CELLS: FROM MGUS TO SYMPTOMATIC MULTIPLE MYELOMA | Ester Lozano op | Received |
264-P | PROTEIN KINASE CK1A INACTIVATION IN MULTIPLE MYELOMA EMPOWERS LENALIDOMIDE INDUCED CYTOTOXICITY AND CELL CYCLE ARREST | Sabrina Manni | Received |
265-P | QUANTIFICATION OF CYCLIN D1, CYCLIN D2, IKAROS, AIOLOS AND CEREBLON PROTEINS BY CAPILARY IMMUNOASSAY IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AND ANALYSIS OF THEIR IMPACT ON PATIENT SURVIVAL | Irena Misiewicz-Krzeminska op | Received |
266-P | DEFERASIROX INDUCES APOPTOSIS THROUGH INHIBITION OF ONCOGENIC PYK2/BETA-CATENIN SIGNALING IN MULTIPLE MYELOMA CELLS | Kohichi Takada op | Received |
267-P | DEVELOPMENT AND IMPLEMENTATION OF A HIGH-THROUGHPUT SEQUENCING BASED, CLINICALLY-FOCUSED, COMPREHENSIVE GENOMIC CHARACTERISATION OF MYELOMA WITHIN A MOLECULAR DIAGNOSTIC SERVICE | Piers Blombery | Received |
276-P | THE SKY92 PROGNOSTIC MARKER IS VALIDATED IN EIGHT MULTIPLE MYELOMA CLINICAL DATASETS | Martin Van Vliet | Received |
279-P | MOR202 ALONE AND IN COMBINATION WITH POMALIDOMIDE OR LENALIDOMIDE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DATA FROM CLINICALLY RELEVANT COHORTS FROM A PHASE I/IIA STUDY | Marc Raab Vliet | Received |
281-P | FINAL PHASE 2 STUDY DATA OF MELFLUFEN AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED-REFRACTORY MULTIPLE MYELOMA (RRMM) | Eva Nordström | Received |
282-P | PRECISION AS PART OF THE ANALYTICAL VALIDATION OF THE SKY92 HIGH RISK SIGNATURE AND THE MMPROFILER ASSAY | Martin Van Vliet | Received |
283-P | RISK STRATIFICATION BY SKY92+ISS OUTPERFORMS IFISH MARKERS T(4;14) AND DEL(17P) IN MULTIPLE MYELOMA | Martin Van Vliet | Received |
284-P | CONSOLIDATION WITH BORTEZOMIB AND LENALIDOMIDE POST-ASCT WITHOUT DEXAMETHASONE AND BISPHOSPHONATES: FINAL ANALYSIS OF A PROSPECTIVE STUDY IN NEWLY DIAGNOSED MYELOMA PATIENTS | Dimitrios Christoulas Vliet | Received |
285-P | LOW INCIDENCE OF SKELETAL-RELATED EVENTS AT THE TIME OF FIRST RELAPSE IN PATIENTS WITH MULTIPLE MYELOMA WHO RECEIVED BORTEZOMIB-BASED REGIMENS AS FIRST LINE TREATMENT | Dimitrios Christoulas Vliet | Received |
287-P | CONCURRENT INHIBITION OF PI3K/MTOR AND JAK1/JAK2 PATHWAYS PROMPTS COMPLETE DEPHOSPHORYLATION OF STAT5 PROVIDING SYNERGISTIC ACTIVITY IN MPN MODELS | Manjola Balliu Vliet | Received |
290-P | LNK MUTATIONS IN FAMILIAL MYELOPROLIFERATIVE NEOPLASMS | Elisa Rumi | Received |
291-P | HOMOZYGOUS CALRETICULIN MUTATIONS IN PATIENTS WITH MYELOFIBROSIS LEAD TO ACQUIRED MYELOPEROXIDASE DEFICIENCY | Alexandre THEOCHARIDES Vliet | Received |
293-P | MESENCHYMAL STROMAL CELLS (MSC) FROM HIGH-GRADE BONE MARROW FIBROSIS PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (PH-NEG MPN) DISPLAY REDUCED CLONOGENICITY AND PROLIFERATION CAPACITY. | Benedetta RAMBALDI Vliet | Received |
294-P | NEXT-GENERATION SEQUENCING IDENTIFIES MPL-TET2 MUTATED CLONES IN A SUBSET OF PATIENTS WITH JAK2V617F-POSITIVE MYELOFIBROSIS | Haifa Kathrin AL-ALI | Received |
297-LB | Christian Pecquet | Received | |
298-P | CLINICAL IMPACT OF ONCOGENETIC PROFILES IN SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGICAL NON-MAST CELL DISEASE. | Carlos Fernandez | Received |
299-P | MUTATIONAL STUDY OF GENES INVOLVED IN MYELOFIBROSIS BY MASSIVE SEQUENCING | Ana Africa Martin | Received |
301-P | PREVENTION OF THROMBOSIS IN PATIENTS WITH POLYCYTHEMIA VERA TREATED WITH HYDROXUYUREA PLUS PHLEBOTOMIES OR HYDROXYUREA ALONE | Alberto Alvarez-Larrán | Received |
302-P | RATE OF MALIGNANT TRANSFORMATION IN HIGH RISK ET DURING 5 YEARS OF FOLLOW-UP OF CYTOREDUCTIVE THERAPY | Gunnar BIRGEGÅRD Martin | Received |
304-LB | C. Harrison | Received | |
309-P | THE LYMPHOMA ASSOCIATED MACROPHAGES-HODGKIN/REED-STERNBERG CELLS RATIO IS A POOR PROGNOSTIC FACTOR IN CLASSIC HODGKIN LYMPHOMA PATIENTS | Vit Prochazka | Received |
310-P | THE PROGNOSTIC ROLE OF BCL-2 EXPRESSION IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA ASSESSED FOR CD68+ CELL COUNT. | Annarosa cuccaro Martin | Received |
312-P | BIOLOGICALLY MEANINGFUL CHANGES IN CYTOKINE AND CHEMOKINE PRODUCTION FOLLOWING IBRUTINIB THERAPY IN WALDENSTROM´S MACROGLOBULINEMIA. | Josephine VOS Martin | Received |
316-P | THE COMBINATION OF IBRUTINIB AND VENETOCLAX (ABT-199) RAPIDLY ACHIEVES COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED / REFRACTORY MANTLE CELL LYMPHOMA: PRELIMINARY RESULTS OF THE PHASE II AIM STUDY | Constantine Tam Martin | Received |
318-P | PHASE 2A STUDY OF THE PHOSPHATIDYLINOSITOL-3-KINASE (PI3K) INHIBITOR COPANLISIB IN PATIENTS WITH RELAPSED/REFRACTORY, INDOLENT OR AGGRESSIVE LYMPHOMA | Dennis Healy Martin | Received |
320-P | SAFETY AND EFFICACY PROFILES OF CLARITHROMYCIN MONOTHERAPY IN 55 PATIENTS WITH EXTRANODAL MARGINAL ZONE LYMPHOMA (EMZL) | Caterina Cecchetti Martin | Received |
322-P | TO SCREEN BIOLOGICAL MARKER GENE ASSOCIATED WITH B CELL IN CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) PATIENTS | Depei Wu Martin | Received |
324-P | MESENCHYMAL STROMAL CELLS STIMULATE THE PROLIFERATION AND IL-22 PRODUCTION BY TYPE 3 INNATE LYMPHOID CELLS | Mette Hazenberg Martin | Received |
325-P | GRANULOCYTE COLONY-STIMULATING FACTOR MOBILIZATION INCREASES THE PROPORTION OF REGULATORY GAMMA DELT T CELLS | Qifa Liu | Received |
326-P | PREACTIVATED MESENCHYMAL STROMAL CELLS IMPROVE T-CELL REGENERATION AFTER THEIR COTRANSPLANTATION WITH HEMATOPOIETIC STEM CELLS | Selim Kuci | Received |
327-P | EVIDENCE OF COMPLEMENT DYSREGULATION IN TRANSPLANT – ASSOCIATED THROMBOTIC MICROANGIOPATHY | Eleni Gavriilaki | Received |
328-P | FAMILY-DIRECTED CORD BLOOD BANKING FOR SICKLE CELL DISEASE: A 20-YEAR EXPERIENCE, ON BEHALF OF EUROCORD-MONACORD AND THE INTERNATIONAL SICKLE CELL DISEASE OBSERVATORY. | Hanadi Rafii Martin | Received |
329-P | CONSOLIDATION BY ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN CR1 AGED 40-69 YEARS: A COMPARISON OF MYELOABLATIVE AND REDUCED INTENSITY CONDITIONING | Aniko Szabo Martin | Received |
330-P | RELAPSED/REFRACTORY HIGH GRADE B CELL NON-HODGKIN LYMPHOMA: SHOULD ONGOING PET POSITIVITY PRECLUDE AUTOLOGOUS TRANSPLANTATION IN PATIENTS ATTAINING A CT RESPONSE TO SALVAGE CHEMOTHERAPY? | Nagah Elmusharaf Martin | Received |
331-P | MARAVIROC CONCENTRATIONS ARE HIGHLY PREDICTIVE OF ACUTE GRAFT-VERSUS-HOST DISEASE IN REDUCED-INTENSITY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | Alex Ganetsky Martin | Received |
332-P | HYPERACUTE GRAFT VERSUS HOST DISEASE: RISK FACTORS, OUTCOMES AND IMPACT OF TACROLIMUS/SIROLIMUS PROPHYLAXIS. | Oriana Lopez | Received |
333-P | REDUCED INTENSITY CONDITIONING TRANSPLANTATION (RIC) AS PART OF FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: RESULTS FROM THE PHASE II MINI ALLO TRIAL (CRUK: C7627/A9080) | Simon Rule | Received |
334-P | THE ROLL OF HYPOMETHYLATING AGENTS IN MYELOID RELAPSES AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANT. | Félix López Cadenas | Received |
335-P | IMPROVED CLINICAL OUTCOMES OF GBM/GPB MIXTURE HAPLOIDENTICAL TRANSPLANTATION WHEN COMPARED TO A PROPENSITY SCORE-MATCHED GPB HAPLOIDENTICAL TRANSPLANTATION: A MULTICENTER STUDY | Xiangyu zhao | Received |
336-P | TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE WITH A COMBINATION OF B-CELL DEPLETION AND TYROSINE KINASE INHIBITION | Lotte VAN | Received |
337-P | FIRST-LINE EXTRACORPOREAL PHOTOCHEMOTHERAPY (ECP) FOR ACUTE GVHD AFTER ALLOGENEIC STEM CELL TRANSPLANTATION | Andrea RIMONDO Godino | Received |
338-P | EFFICACY OF HOST-DENDRITIC CELL VACCINATIONS WITH AND WITHOUT MINOR HISTOCOMPATIBILITY ANTIGEN LOADING, COMBINED WITH DONOR LYMPHOCYTE INFUSION IN MULTIPLE MYELOMA PATIENTS | Rimke Oostvogels DER | Received |
339-P | TRACING OF URINARY EXCRETION OF BKV AND JCV BY QUANTITATIVE PCR IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTS (ALLO-HSCT) TO ANTICIPATE THE DEVELOPMENT OF HEMORRHAGIC CYSTITIS (HC). | Joud Zanabili Al-Sibai | Received |
340-P | OUTCOMES AFTER AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) PATIENTS WITH MYC/BCL2 CO-EXPRESSION, DOUBLE-HIT LYMPHOMA, OR MYC COPY GAIN | Alex Herrera Al-Sibai | Received |
341-P | BTLA GENOTYPE AND CLINICAL OUTCOME AFTER HLA-IDENTICAL SIBLING STEM CELL TRANSPLANTATION | Nazly Santos Al-Sibai | Received |
342-P | HIGH-DOSE VERSUS STANDARD-DOSE RITUXIMAB WITH BEAM IN AUTOLOGOUS STEM CELL TRANSPLANTATION (SCT) FOR RELAPSED AGGRESSIVE B-CELL NON-HODGKIN´S LYMPHOMAS (NHL) | Samer Srour Al-Sibai | Received |
345-P | HIGH DOSE CHEMOTHERAPY WITH AUTOGRAFT MAY IMPROVE THE POOR PROGNOSIS OF NAIVE DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS WITH MYC/BCL2 CO-EXPRESSION | Francesco Maura Al-Sibai | Received |
346-P | BIOMARKERS PREDICTING ACUTE GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A PROSPECTIVE STUDY IN 120 PATIENTS | Linda Cheyenne | Received |
348-P | TRANSPLANTATION FROM MATCHED UNRELATED AND HAPLOIDENTICAL DONOR IN PEDIATRIC SEVERE APLASTIC ANEMIA: EXPERIENCE WITH TCR ALPHA/BETA AND CD19 DEPLETION AS GRAFT PROCESSING METHOD. | Daria SHASHELEVA Vaccari | Received |
350-P | HHEX PROMOTES HSC SELF-RENEWAL AND STRESS HEMATOPOIESIS VIA REPRESSION OF CDKN2A | Jacob T Jackson | Received |
352-P | NPM1 IS REQUIRED FOR NORMAL HEMATOPOIESIS | Chow Hiang Ang | Received |
353-P | PLZF MUTATION ALTERS MOUSE HEMATOPOIETIC STEM CELL FUNCTION AND CELL CYCLE PROGRESSION | Christelle VINCENT-FABERT Ang | Received |
354-P | IL-1 INDUCED ACTIVATION OF QUIESCENT HEMATOPOIETIC STEM CELLS IN VIVO | Uta Demel Vaccari | Received |
356-P | CLEC-2 EXPRESSION IS A NEW MARKER FOR A SUBSET OF HEMATOPOIETIC STEM/PROGENITOR CELLS THAT CONTRIBUTES TO INFLAMMATION-INDUCED EMERGENT MEGAKARYOPOIESIS | Takahiro Kumode Vaccari | Received |
357-P | IN VITRO AND IN VIVO STEM CELL PROPERTIES OF HIGHLY ENRICHED HUMAN BONE MARROW MESENCHYMAL STROMAL CELLS | Roshanak Ghazanfari | Received |
358-P | GENOME WIDE DYSREGULATION OF GENE EXPRESSION BY TRISOMY 21 IN FETAL LIVER HAEMATOPOIETIC STEM AND PROGENITOR CELLS | Anindita Roy Vaccari | Received |
359-P | GPR56: A NOVEL MOLECULE INVOLVED IN HEMATOPOIETIC STEM CELL GENERATION | Emma DE PATER | Received |
364-P | CORD BLOOD DERIVED NK CELLS TRANSFER HISTONE H2AZ TO MULTIPLE MYELOMA CELLS CAUSING DIRECT AND INDIRECT CYTOTOXICITY | Beatriz Martín-Antonio PATER | Received |
365-P | ALLOGENEIC TCRA/CD38 DOUBLE KNOCKOUT T-CELLS BEARING AN ANTI-CD38 CHIMERIC ANTIGEN RECEPTOR: AN IMPROVED IMMUNOTHERAPY FOR THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND MULTIPLE MYELOMA. | Mathilde Dusseaux PATER | Received |
366-P | OPTIMIZED AAV-MEDIATED HUMAN FACTOR VIII GENE THERAPY IN HEMOPHILIA A MICE AND CYNOMOLGUS MACAQUES | James Wilson PATER | Received |
367-P | A DOSE-ESCALATING PRECLINICAL STUDY TO DETERMINE THE SAFETY, EFFICACY, AND MINIMUM EFFECTIVE DOSE OF A CLINICAL CANDIDATE VECTOR IN A MOUSE MODEL OF HEMOPHILIA B | James Wilson PATER | Received |
368-P | THE LCR-FREE GAMMA-GLOBIN LENTIVIRAL VECTOR COMBINING TWO HPFH ACTIVATING ELEMENTS CORRECTS MURINE THALASSEMIC PHENOTYPE IN VIVO | Nicholas Anagnou | Received |
369-P | BALANCE OF ANTI-CD123 CHIMERIC ANTIGEN RECEPTOR (CAR) BINDING AFFINITY AND DENSITY IN AN IN VITRO MODEL OF ACUTE MYELOID LEUKEMIA | Silvia Arcangeli | Received |
370-P | PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF GBT440, A NOVEL HEMOGLOBIN S (HBS) POLYMERIZATION INHIBITOR FOR THE TREATMENT OF SICKLE CELL DISEASE (SCD), IN HEALTHY VOLUNTEERS AND SCD PATIENTS | Mira Patel PATER | Received |
372-P | CEREBROVASCULAR RESERVE IN SICKLE CELL DISEASE ASSESSED WITH PERFUSION MAGNETIC RESONANCE IMAGING | Lena Vaclavu | Received |
373-P | RESTING STATE FUNCTIONAL MRI SHOWS HOW COGNITIVE PERFORMANCES COULD BE PRESERVED IN CHILDREN WITH SICKLE CELL DISEASE | Raffaella Colombatti PATER | Received |
377-P | ASSOCIATION BETWEEN ENVIRONMENTAL FACTORS AND HOSPITAL ADMISSIONS FOR SICKLE CELL DISEASE: A RETROSPECTIVE TIME SERIES ANALYSIS | Sanjay Tewari PATER | Received |
378-P | MULTICENTER, PROSPECTIVE, RANDOMIZED TRIAL OF INTRAVENOUS ITRACONAZOLE VS. LIPOSOMAL AMPHOTERICIN B AS EMPIRICAL ANTIFUNGAL THERAPY FOR HEMATOLOGICAL MALIGNANCY WITH PERSISTENT FEVER AND NEUTROPENIA | Isao Yoshida PATER | Received |
379-P | PREVALENCE, STRUCTURE, AND PUTATIVE MECHANISM FOR TEMPLATED INSERTIONS IN VDJ RECOMBINATION | Marvyn Koning PATER | Received |
380-P | FLUOROQUINOLONE PROPHYLAXIS SIGNIFICANTLY AFFECTS BACTERIAL EPIDEMIOLOLOGY AND ANTIBIOTIC RESISTANCE BUT DOES NOT IMPACT ON INCIDENCE AND MORTALITY OF BLOODSTREAM INFECTIONS IN ACUTE LEUKAEMIA | Chiara CATTANEO PATER | Received |
383-P | INVASIVE FUNGAL INFECTIONS IN LYMPHOPROLIFERATIVE DISORDERS: REVISION OF INCIDENCE IN THE "MODERN TREATMENT" ERA | Maria Chiara Tisi | Received |
384-P | INFECTIOUS AND THROMBOTIC COMPLICATIONS IN PERIPHERALLY INSERTED (PICCS) COMPARED TO SHORT TERM CENTRAL VENOUS CATHETERS IN ONCOHEMATOLOGIC PATIENTS: A REL GROUP (RETE EMATOLOGICA LOMBARDA) STUDY | Nicola Stefano Fracchiolla | Received |
385-P | USEFULNESS OF SERUM 1,3-B-D-GLUCAN FOR DIAGNOSIS OF INVASIVE FUNGAL DISEASE IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A RETROSPECTIVE ANALYSIS | Barbora Weinbergerova Fracchiolla | Received |
386-P | DIFFERENT ISOFORM LOCALIZATION GOVERNS SIGNALING QUALITY OF DECTIN-1 IN THE REGULATION OF ANTI-FUNGAL IMMUNITY | Ulf Schnetzke Fracchiolla | Received |
387-P | PRELIMINARY REPORT OF FUNGEMIA IN HEMATOLOGICAL MALIGNANCIES FROM SEIFEM-2015 SURVEY | Marianna Criscuolo Fracchiolla | Received |
388-P | PROGNOSTIC FACTORS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES ADMITTED TO THE INTENSIVE CARE UNIT: EXPERIENCE WITH 335 PATIENTS FROM A SINGLE CENTER | Alfredo Rivas-Delgado Fracchiolla | Received |
389-P | SAFETY AND EFFICACY OF HUMAN T-LYMPHOTROPIC VIRUS 1 (HTLV-1) HYPERIMMUNE GLOBULIN AGAINST HTLV-1 INFECTION IN A HUMANIZED MOUSE MODEL. | Takuo Mizukami Fracchiolla | Received |
391-P | AUDIT OF TRANSFUSION PRACTICES IN PATIENTS RECEIVING AUTOLOGOUS STEM CELL TRANSPLANTATION AT UNIVERSITY HOSPITALS BIRMINGHAM | Aine BURKE Fracchiolla | Received |
393-P | IMPACT OF PROTHROMBIN COMPLEX CONCENTRATE (PCC) USE ON TRANSFUSION REQUIREMENTS AND BLOOD LOSS IN CARDIAC SURGERY | Allison Mo Fracchiolla | Received |
394-P | COMBINED PLASMA EXCHANGE AND ERYTHROCYTAPHERESIS FOR TREATMENT OF MULTIORGAN FAILURE DUE TO SUSPECTED FAT EMBOLISM SYNDROME IN SICKLE CELL DISEASE | Daniele Avenoso Fracchiolla | Received |
396-P | EFFECTS OF IMPLEMENTATION OF A MASSIVE TRANSFUSION PROTOCOL IN A TERTIARY REFERRAL HOSPITAL | Ioannis Giannoutsos Fracchiolla | Received |
397-P | LOW PREVALENCE OF ALLOIMMUNIZATION AFTER RED BLOOD CELL TRANSFUSION IN 182 CHILDREN WITH SICKLE CELL DISEASE. | Slimane Allali Fracchiolla | Received |
402-P | NEW MUTATION C.-140C>G IN 5´UTR OF ANKRD26 GENE IN PATIENTS WITH MILD FORM OF INHERITED THROMBOCYTOPENIA ASSOCIATED WITH MALIGNANCIES. | Silvia FERRARI Fracchiolla | Received |
403-P | MYCHOFENOLATE MOFETILE FOR THE TREATMENT OF CHILDREN WITH IMMUNE THROMBOCYTOPENIA AND EVANS SYNDROME. A RESTROSPECTIVE STUDY OF THE ITALIAN ASSOCIATION OF PEDIATRIC HEAMATOLOGY/ONCOLOGY GROUP | Maurizio Miano Fracchiolla | Received |
406-P | THE IMMUNOMODULATORY EFFECTS OF RETINIC ACID IN ADULT PATIENTS WITH IMMUNE THROMBOCYTOPENIA | Qi Feng | Received |
407-P | STUDIES ON PLATELET FUNCTION IN A GROUP OF CLL AND MCL PATIENTS TREATED WITH IBRUTINIB - PRELIMINARY RESULTS | Darek Jawniak Vaccari | Received |
408-P | CLINICAL CHARACTERISTICS AND TREATMENT PATTERN OF NEWLY DIAGNOSED PRIMARY IMMUNE THROMBOCYTOPENIA CASES IN THE UNITED KINGDOM IMMUNE THROMBOCYTOPENIA (ADULT) REGISTRY | Indraraj Umesh Doobaree | Received |
409-P | EFFICACY AND SAFETY OF RIVAROXABAN FOR NON-VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH SEVERE RENAL IMPAIRMENT | Sara Ali Doobaree | Received |
410-P | ORAL DIRECT ANTICOAGULANTS IN THE TREATMENT OF NONVALVULAR ATRIAL FIBRILLATION. RESULTS OF THE DAILY CLINICAL PRACTICE | Beatriz Perez Villardon | Received |
411-P | SWITCH FROM VKA, LMWH OR FONDAPARINUX TO DOACS IN THE CLINICAL PRACTICE. | Francesco cortiula Villardon | Received |
412-P | HIGH HEMOGLOBIN CONCENTRATIONS AND RISK OF THROMBOSIS: CAUSALITY OR CONFOUNDING? | Sæmundur Rögnvaldsson Villardon | Received |
414-P | ANNEXIN A5 M2 HAPLOTYPE: TO BE OR NOT TO BE, THAT´S THE QUESTION! | Rita Tenreiro Villardon | Received |
415-P | IRON METABOLISM IN PATIENTS WITH PORTAL THROMBOSES | Elena Lukina Villardon | Received |
416-P | PERIPHERALLY INSERTED CENTRAL VENOUS CATHETER-RELATED VENOUS THROMBOSIS IN PATIENTS WITH HEMATOLOGICAL DISEASES | Ana BOBAN Villardon | Received |
417-P | EQUATIONS FOR ESTIMATING GFR: COMPARING RENAL FUNCTION CATEGORISATION IN THE CATCH STUDY | Mette Stagaard Janas | Received |
418-P | A PROSPECTIVE EVALUATION OF THE IMPACT OF TRANSFUSION DEPENDENCY ON QUALITY OF LIFE AND SYMPTOM BURDEN IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES | Francesco Sparano Janas | Received |
422-P | PATIENT PREFERENCES, SURVEY OF HODGKIN LYMPHOMA SURVIVORS ON TREATMENT, ASSOCIATED BURDEN AND SIDE EFFECTS | Carolin Buerkle | Received |
423-P | UNDERESTIMATED IMPACT OF MILD COGNITIVE IMPAIRMENT IN "CLINICALLY FIT" OLDER PATIENTS WITH MALIGNANT HEMOPATHIES ADMITTED TO RECEIVE CHEMOTHERAPY | Dominique Bron Janas | Received |
424-P | WHAT DO PATIENT EXPERIENCE DATA REVEAL ABOUT THE DIAGNOSTIC JOURNEY FOR MYELOMA PATIENTS? FINDINGS FROM SECONDARY ANALYSIS OF NATIONAL CANCER PATIENT SURVEY DATA | Sarah Richard Janas | Received |
425-P | STREAMLINING OF THE CHEMOTHERAPY SERVICE WITH FOCUS ON DRUG SUPPLY AND PATIENT SAFETY | Heike Reinhardt Janas | Received |
426-P | INTERIM QUALITY OF LIFE RESULTS WITH VENETOCLAX (ABT-199/GDC-0199) MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DEL(17P) CHRONIC LYMPHOCYTIC LEUKEMIA | Ling-I HSU Janas | Received |
526-P | IN VIVO ROLE OF ACTIVATION INDUCED CYTIDINE DEAMINASE (AID) EXPRESSION IN THE DEVELOPMENT OF PRECURSOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | Franziska Auer | Received |
528-P | THE HISTONE DEACETYLASE INHIBITOR GIVINOSTAT (ITF2357) HAS A POTENT ANTI-TUMOR ACTIVITY AGAINST CRLF2 REARRANGED LEUKEMIA | Giovanni Cazzaniga Janas | Received |
529-P | INSIGHTS INTO THE MOLECULAR EVOLUTION OF BCR-ABLP190 MEDIATED PRECURSOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | Franziska Auer Vaccari | Received |
530-P | THE ROLE OF CNOT3 AND THE ENTIRE CCR4-NOT COMPLEX IN TUMOR DEVELOPMENT | Carmen VICENTE | Received |
531-P | CAPTURE-BASED NEXT GENERATION SEQUENCING (NGS) IDENTIFIES ALSO RARE IG/TCR REARRANGEMENTS IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS | Marie Lorena | Received |
532-P | MIR-126 DRIVEN LEUKEMIA: A MURINE MODEL TO UNDERSTAND HUMAN B-ALL PATHOGENESIS | Matteo Maria | Received |
533-P | MUTATIONS IN TP53 AND JAK2 GENES ARE ASSOCIATED WITH POOR PROGNOSIS IN PEDIATRIC AND ADULT PATIENTS WITH B-CELL PRECURSOR ALL | Cristina Robledo | Received |
536-P | TARGETING BET FAMILY PROTEINS IMPROVES THE THERAPEUTIC EFFICACY OF BCL-2 INHIBITION IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | Sofie PEIRS NALDINI | Received |
538-P | DELETIONS OF IKZF1 GENE, BUT NOT GENETIC RISK GROUPS, DEFINED BY COPY-NUMBER ALTERATIONS, ARE PROGNOSTICALLY SIGNIFICANT FOR PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA ON ALL-MB 2008 PROTOCOL | Grigory TSAUR NALDINI | Received |
539-P | LACK OF PROGNOSTIC SIGNIFICANCE OF CD20 EXPRESSION IN ADULTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE, B-CELL PRECURSOR ALL TREATED ACCORDING TO MRD-ORIENTED PROTOCOLS | Josep Maria | Received |
541-P | PRELEUKEMIC CLONES IN NPM1-MUTATED AML MAY BE ASSOCIATED WITH EVOLUTION TO MYELODYSPLASTIC SYNDROME (MDS) OR MYELOPROLIFERATIVE NEOPLASM (MPN) | Sarah morin | Received |
542-P | CLINICAL, HEMATOLOGICAL, BIOLOGIC AND MOLECULAR CHARACTERISTICS IN PATIENTS WHO DEVELOP ACUTE MYELOID LEUKEMIA FROM CHRONIC MYELOMONOCYTIC LEUKEMIA | Temeida Alendar Ribera | Received |
544-P | SOMATIC DDX41 P.R525H MUTATION CAUSES GROWTH DEFECT IN HEMATOPOIETIC CELLS | Hirotaka Matsui | Received |
545-P | WHOLE EXOME SEQUENCING REVEALS NOVEL CANDIDATE GENES IN FAMILIAL MDS/AML | Ana Rio-Machin Ribera | Received |
547-P | POOR PROGNOSIS MONOSOMIC AND TRISOMIC ACUTE MYELOID LEUKEMIA ASSOCIATES WITH CHECKPOINTS AND CDC20 DEREGULATION: A NOVEL LEUKEMOGENIC MECHANISM AND THERAPEUTIC TARGETS | Giorgia Simonetti Ribera | Received |
549-P | PHYSIOPATHOLOGICAL MECHANISM OF LEUKEMIC PREDISPOSITION IN ANKRD26-RD PATIENTS | Alessandro Donada | Received |
550-P | NOTCH SIGNALLING INHIBITION AS A MULTI-TARGET THERAPY TO OVERCOME BONE MARROW MICROENVIRONMENT-MEDIATED DRUG RESISTANCE IN AML | Paul Takam Kamga | Received |
552-P | ENANTIOMER-SPECIFIC AND PARACRINE LEUKEMOGENICITY OF MUTANT IDH METABOLITE 2-HYDROXYGLUTARATE | Anuhar Chaturvedi | Received |
553-P | INVOLVEMENT OF THE TRANSCRIPTION FACTOR ASCL2 IN NORMAL AND LEUKEMIC HEMATOPOIESIS | Mallorie Dépond Kamga | Received |
555-P | IN VIVO SHRNA SCREEN IDENTIFIES SPLICING FACTOR RBM25 AS A TUMOR SUPPRESSOR IN ACUTE MYELOID LEUKEMIA | Ying Ge | Received |
556-P | HIGH MTORC1 ACTIVITY DRIVES GLUCOSE METABOLISM ADDICTION AND SENSITIVITY TO G6PD INHIBITION IN ACUTE MYELOID LEUKEMIA CELLS | Laury Poulain | Received |
559-P | IDENTIFICATION OF A NOVEL STAT5 INHIBITOR TO INTERFERE WITH THE ONCOGENIC ACTIVITIES OF STAT5 IN AML | Bettina Wingelhofer | Received |
561-P | DOUBLE INACTIVATION OF TET2 AND TET3 INDUCES HYPOMETHYLATING AGENT-SENSITIVE ACUTE MYELOID LEUKEMIA | Koichiro Maie Kamga | Received |
562-P | NGS IDENTIFIES MUTATIONS PROGNOSTIC OF RELAPSE AFTER ALLO-SCT AND NOVEL CLONE EMERGENCE AT DISEASE RECURRENCE: IMPLICATIONS FOR STRATEGIES TO PREVENT POST ALLO-SCT RELAPSE. | Lynn Quek Kamga | Received |
563-P | HIGH PREDICTIVE VALUE OF COMBINED WT1 AND FLOW CYTOMETRY-BASED PRE TRANSPLANT MINIMAL RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA | Fabio Guolo | Received |
565-P | DNMT3A AND IDH1 MUTATIONS WORSEN THE PROGNOSIS OF ELN GOOD RISK (CEBPA OR NPM1 MUTATED/FLT3 UNMUTATED) AML PATIENTS | Jana Marková Ribera | Received |
567-P | NANOG EXPRESSION AS A RESPONSIVE BIOMARKER DURING TREATMENT WITH HEDGEHOG SIGNAL INHIBITOR IN ACUTE MYELOID LEUKEMIA | Seiji Kakiuchi | Received |
569-P | AN EX VIVO NATIVE ENVIRONMENT PRECISION MEDICINE TEST SHOWS HIGH CLINICAL CORRELATION WITH RESPONSES TO FIRST LINE ACUTE MYELOID LEUKEMIA TREATMENT | Ana Espinosa | Received |
570-P | RECURSIVE PARTITIONING ANALYSIS FOR GENETIC STRATIFICATION AND PROGNOSTICATION OF ACUTE MYELOID LEUKAEMIA | Shaun Fleming Kamga | Received |
571-P | CD7 AND CD34 CO-EXPRESSION IDENTIFY A SUBPOPULATION OF NUCLEOPHOSMIN 1-MUTATED ACUTE MYELOID LEUKEMIA (NPM1+ AML) PATIENTS WITH INCREASED RISK OF RELAPSE. | Anna Porwit | Received |
575-P | THE ADDITION OF GEMTUZUMAB OZAGAMICIN (GO) TO INTENSIVE CHEMOTHERAPY SIGNIFICANTLY IMPROVES COMPLETE RESPONSES CR RATES AND OVERALL SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA | Giovanni Martinelli | Received |
577-P | PHARMACEUTICAL TARGETING OF PYRUVATE DEHYDROGENASE KINASES IN T(8;21) ACUTE MYELOID LEUKEMIA | Hüsün Kizilkaya Kamga | Received |
578-P | HOPX IS A HEMATOPOIETIC STEM CELL MARKER AND ITS HIGH EXPRESSION PREDICTS CHEMORESISTANCE IN DE NOVO ACUTE MYELOID LEUKEMIA PATIENTS | Chien-Chin Lin | Received |
580-P | LONGITUDINAL EVALUATION OF T-CELLS IN CLINICAL MONOCLONAL B-CELL LYMPHOCYTOSIS (MBL) | Sameer A. Parikh | Received |
580-LB | Mohamed Sorror | Received | |
581-P | COPY NUMBER ANALYSIS OF THE BIRC3 GENE BY DROPLET DIGITAL PCR IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH 11Q DELETION | Sara Raponi | Received |
586-P | IMPROVING THE DIFFERENTIAL DIAGNOSIS OF CD5+ B-LYMPHOPROLIFERATIVE DISORDERS | Andy Rawstron Parikh | Received |
587-P | REFINED KARYOTYPE-BASED PROGNOSTIC STRATIFICATION OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH A VERY LOW RISK GENETIC PROFILE | Ilaria Del Giudice | Received |
588-P | PRO-APOPTOTIC EFFECTS OF PRIMA-1MET CORRELATE WITH NOXA GENE INDUCTION IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS | Zuzana Jaskova Giudice | Received |
589-P | PILOT STUDY TO ASSESS REAGENT AND INSTRUMENT QUALITY FOR REPRODUCIBLE DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA: AN ESCCA AND ERIC HARMONISATION PROJECT | Andy Rawstron | Received |
590-P | THE SYK\JAK INHIBITOR CERDULATINIB SHOWS PROMISING IN VITRO ACTIVITY IN CHRONIC LYMPHOCYTIC LEUKEMIA | Andrew STEELE | Received |
592-P | IBRUTINIB FOR RELAPSED CLL PATIENTS OLDER THAN 75 YEARS: PROVEN EFFICACY, TOXICITIES TO KNOW | Anne-Sophie MICHALLET Giudice | Received |
595-P | CHROMOSOME 8 ABNORMALITIES ARE ASSOCIATED WITH AN EVEN WORSE OUTCOME AND KARYOTYPE COMPLEXITY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND TP53 ABERRATIONS | Gonzalo Blanco | Received |
598-P | NO IMPROVEMENT IN LONG-TERM OVERALL SURVIVAL AFTER THE INTRODUCTION OF CHEMO(IMMUNO)THERAPY FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS BELONGING TO STEREOTYPED SUBSET #2 | Panagiotis Baliakas Giudice | Received |
601-P | ROCK AS THERAPEUTICAL TARGET FOR MORGANA LOW CML | Stefania Rocca | Received |
602-P | A NOVEL C-TERMINAL HSP90 INHIBITOR WITH THERAPEUTIC EFFECT IN IMATINIB RESISTANT CML. | Sanil Bhatia Ribera | Received |
604-P | MITOCHONDRIAL DNA MUTATIONS IDENTIFY CLONAL HETEROGENEITY IN CHRONIC MYELOID LEUKAEMIA | Ilaria Stefania Pagani | Received |
605-P | CLONAL STRUCTURES OF LEUKAEMIA STEM CELL POPULATIONS IN MYELOID BLAST PHASE CHRONIC MYELOID LEUKAEMIA | Dimitrios Karamitros Pagani | Received |
606-P | ROLE OF THE AURORA KINASE A AXIS IN IMATINIB RESISTANCE OF CHRONIC MYELOID LEUKEMIA CD34+ PROGENITORS | Manuela Mancini Pagani | Received |
610-P | THE INCIDENCE AND NATURAL HISTORY OF DASATINIB COMPLICATIONS IN THE TREATMENT OF CHRONIC MYELOID LEUKAEMIA | Lucy Fox Pagani | Received |
611-P | THE HOCT1/ABCB1 DIPLOTYPE IS ASSOCIATED WITH COMPLETE CYTOGENETIC RESPONSE AND TOLERABILITY TO IMATINIB IN PATIENTS AFFECTED BY CHRONIC MYELOID LEUKEMIA | Sara Galimberti Pagani | Received |
612-P | REAL-LIFE COMPARISON OF DASATINIB AND NILOTINIB AS SECOND-LINE THERAPY AFTER IMATINIB FAILURE FOR CHRONIC PHASE CML | Mario Tiribelli Pagani | Received |
613-P | FACTORS THAT INFLUENCE PATIENT WILLINGNESS TO ATTEMPT TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKAEMIA | David Ross Pagani | Received |
614-P | GENETIC VARIABILITY OF OXIDATIVE STRESS AND DNA REPAIR GENES – POTENTIAL PROGNOSTIC AND THERAPEUTIC BIOMARKERS IN CHRONIC MYELOID LEUKEMIA | Ana Cristina Gonçalves | Received |
616-P | BCR-ABL1 TRANSCRIPT LEVEL ON DAY+28 CAN PREDICT EARLY MOLECULAR RESPONSE AT 3 MONTHS AND MAJOR MOLECULAR RESPONSE AT 12 MONTHS IN CHRONIC MYELOID LEUKEMIA PATIENTS WHO TREATED WITH FRONTLINE DASATINIB | Won Sik LEE | Received |
619-P | IMPACT OF BONE MARROW FIBROSIS IN RESPONSE TO AZACITIDINE IN 94 PATIENTS WITH MYELODISPLASTIC SYNDROMES (MDS), CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) AND ACUTE MYELOID LEUKEMIA | Alessandra Freyrie Gonçalves | Received |
620-P | AGE DISTRIBUTION OF PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) IN GERMANY AND THEIR PROGNOSIS ACCORDING TO THE INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS): DATA FROM THE REGULAR CARE MDS REGISTRY | H Tilman Steinmetz | Received |
621-P | VALIDATION OF PROGNOSTIC SCORING SYSTEMS FOR MYELODYSPLASTIC SYNDROMES IN THE SWEDISH MDS-REGISTER | Daniel Moreno Berggren | Received |
622-P | EXPRESSION OF TUBB GENE IN MYELODYSPLASTIC SYNDROME WITH OR WITHOUT EVOLUTION TO LEUKEMIA | Yan MA Berggren | Received |
623-P | HIDDEN MDS: A PROSPECTIVE STUDY TO CONFIRM OR EXCLUDE MDS IN PATIENTS WITH ANEMIA OF UNCERTAIN ETIOLOGY. | Bastida Jose Maria | Received |
625-P | CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES (MDS) IN DAILY PRACTICE: A POPULATION-BASED STUDY AMONG 8912 PATIENTS DIAGNOSED IN THE NETHERLANDS FROM 2001 TO 2014 | Avinash Dinmohamed Maria | Received |
626-P | LEVELS OF TRANSFUSION BURDEN AND ASSOCIATED COSTS FOR PATIENTS WITH TRANSFUSION-DEPENDENT MYELODYSPLASTIC SYNDROMES | Amy DeZern Maria | Received |
627-P | THE INCORPORATION OF COMORBIDITIES IN THE PROGNOSTICATION OF PATIENTS WITH LOWER-RISK MDS. | Teresa Knight Asorey | Received |
628-P | STROMAL MICROENVIRONMENT COMPONENTS DAMAGE IN PATIENTS WITH GRAFT FAILURE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION | Nataliya PETINATI | Received |
629-P | SPONTANEOUS REMISSION IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA - RETURN TO HEALTH OR TRANSITION INTO MALIGNANCY? | Eva-Stina Kairemo Asorey | Received |
632-P | A PHASE 1 SINGLE-ASCENDING-DOSE CLINICAL STUDY OF RA101495, A SUBCUTANEOUSLY ADMINISTERED SYNTHETIC MACROCYCLIC PEPTIDE INHIBITOR OF COMPLEMENT C5 FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA | Jeffrey Johnston Asorey | Received |
633-P | THE PRESENCE OF A PNH CLONE INFLUENCES THE KINETICS OF RESPONSE TO IMMUNOSUPPRESSIVE THERAPY (IST) IN APLASTIC ANEMIA (AA) PATIENTS. | Thomas Nevill Asorey | Received |
638-P | IKAROS PROTEIN EXPRESSION IN BONE MARROW B AND T CELLS RATHER THAN MYELOMA CELLS PREDICTS OUTCOME AFTER LENALIDOMIDE-DEXAMETHASONE THERAPY | Arnold Bolomsky Asorey | Received |
639-P | CXCL13 CHEMOKINE – A NOVEL TARGET IN MULTIPLE MYELOMA MICROENVIRONMENT | Katia BEIDER Asorey | Received |
640-P | MESENCHYMAL STEM CELLS (MSC) PROMOTES TUMOR MICROENVIRONMENT TRANSFORMATION DRIVING GRANULOCYTE-LIKE MYELOID DERIVED SUPPRESSOR CELLS (G-MDSC) ACTIVATION IN SMOLDERING AND MULTIPLE MYELOMA PATIENTS | Daniele Tibullo Asorey | Received |
641-P | TARGETING OF BMI-1 WITH PTC-209 AFFECTS MYELOMA CELL GROWTH & SURVIVAL AND IMPAIRS THE TUMOUR MICROENVIRONMENT | Arnold Bolomsky Asorey | Received |
642-P | LENALIDOMIDE MAINTENANCE COUNTERACTS PD-1 ELEVATION ON LYMPHOCYTES IN MYELOMA PATIENTS | Sophia Danhof Maria | Received |
643-P | CIRCULATING SERUM MIRNA PROFILE IN AL AMYLOIDOSIS | Fedor Kryukov | Received |
644-P | PRECLINICAL EVALUATION OF ABBV-838, A FIRST-IN-CLASS ANTI-CS1 ANTIBODY-DRUG CONJUGATE FOR THE TREATMENT OF MULTIPLE MYELOMA | Kurt Gish Asorey | Received |
648-P | PHASE 1B STUDY OF AN ALTERNATIVE LIQUID FORMULATION OF ACY-1215 (RICOLINOSTAT) IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR RELAPSED-AND-REFRACTORY MULTIPLE MYELOMA | Tyce Havens | Received |
650-P | OUTCOME OF MYELOMA PATIENTS WITH DELETION 17P – IMPACT OF BASELINE CHARACTERISTICS, TREATMENT AND ADDITIONAL CHROMOSOMAL CHANGES | Maximilian Merz | Received |
651-P | CIRCULATING TUMOR DNA IN MULTIPLE MYELOMA | Even Holth Rustad | Received |
654-P | PROSPECTIVE COMORBIDITY AND FUNCTIONAL GERIATRIC ASSESSMENT (CF-GA) IN MULTIPLE MYELOMA (MM) PATIENTS (PTS): RESULTS FROM A MULTICENTER GERMAN STUDY GROUP MM (DSMM) TRIAL | Sandra Dold Rustad | Received |
657-P | PROSPECTIVE EVALUATION OF GERIATRIC ASSESSMENT TOOLS IN REAL-WORLD, UNSELECTED, ELDERLY PATIENTS WITH SYMPTOMATIC MYELOMA | Efstathios Kastritis | Received |
665-P | PROGNOSTIC FACTORS IN PATIENTS WITH MULTIPLE MYELOMA AND STANDARD-RISK CYTOGENETICS | Moritz Binder | Received |
666-P | CLINICAL CHARACTERISTICS AND LONG-TERM OUTCOME ON IMATINIB IN PATIENTS WITH MYELOID/LYMPHOID NEOPLASMS AND ASSOCIATED PDGFRB FUSION GENES IN CHRONIC OR BLAST PHASE | Georgia METZGEROTH Rustad | Received |
667-P | THROMBOTIC RISK IN IDIOPATHIC ERYTHROCYTOSIS IS LOWER THAN IN POLYCYTHEMIA VERA BUT HIGHER THAN IN GENERAL POPULATION. | Maria Luigia Randi | Received |
669-P | COMPARISON OF GENOMIC DNA-BASED VS. MESSENGER RNA-BASED KIT D816V MUTATION ANALYSIS REVEALS LARGE DIFFERENCES BETWEEN BLOOD AND BONE MARROW IN SYSTEMIC MASTOCYTOSIS | Thomas Kristensen Randi | Received |
670-P | 3167 NEWLY DIAGNOSED MPN PATIENTS, A REPORT FROM THE SWEDISH MPN REGISTRY | Björn Andreasson Randi | Received |
671-P | PREDICTIVE ROLE OF CIRCULATING LEUCOCYTE-PLATELET AGGREGATES FOR THROMBOEMBOLIC COMPLICATIONS IN PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS: A PROSPECTIVE STUDY | Dijana Šefer | Received |
672-P | PREDICTORS FOR RESPONSE TO RUXOLITINIB IN REAL-LIFE: AN OBSERVATIONAL INDEPENDENT STUDY ON 266 PATIENTS WITH MYELOFIBROSIS | Nicola Polverelli | Received |
676-P | PROGNOSTIC IMPACT OF INTEGRATED GENOMIC PROFILING IN ADULT T-CELL LEUKEMIA/LYMPHOMA | Keisuke Kataoka | Received |
677-P | HNRNP K: A NOVEL ONCOGENE THAT DRIVES C-MYC-DEPENDENT LYMPHOMAS AS A POTENTIAL THERAPY TARGET | Miguel Gallardo Randi | Received |
678-P | GENOMIC PROFILING REVEALS SPATIAL HETEROGENEITY IN FOLLICULAR LYMPHOMA: IMPLICATIONS FOR PRECISION MEDICINE. | Shamzah Araf Randi | Received |
679-P | SOMATIC MUTATION PROFILING FOR PROGNOSIS AND TREATMENT STRATIFICATION OF DIFFUSE LARGE B-CELL LYMPHOMA IN THE REMODL-B TRIAL | Ming Qing Du | Received |
680-P | ADHESION MOLECULE JAM-C: A POTENTIAL TARGET FOR MANTLE CELL LYMPHOMA THERAPEUTICS | Thomas Matthes Randi | Received |
681-P | ATM GENE MUTATIONS REPRESENT A HALLMARK OF MANTLE CELL LYMPHOMA BUT DO NOT IMPACT PATIENTS´ SURVIVAL | Andrea MARECKOVÁ Randi | Received |
683-P | TP53 AND KMT2D MUTATIONS PREDICT PFS IN MCL PATIENTS TREATED WITH HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION: RESULTS FROM THE MCL0208 PHASE III TRIAL FROM FONDAZIONE ITALIANA LINFOMI (FIL) | Simone Ferrero | Received |
684-P | DECIPHERING THE IMPACT OF IDELALISIB ON FOLLICULAR LYMPHOMA AND ITS IMMUNE MICROENVIRONMENT | Patricia Pérez-Galán Randi | Received |
685-P | MIR-34A PREVENTS LUNG INJURY IN BLEOMYCIN INDUCED PULMONARY FIBROSIS | Raanan Bulvik Du | Received |
686-P | INTERIM ANALYSIS OF POST MARKETING SURVEILLANCE OF YTTRIUM-90 IBRITUMOMAB TIUXETAN IN JAPANESE PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA OR MANTLE CELL LYMPHOMA | Rumiko Kanzaki Randi | Received |
687-P | PATIENTS WITH FOLLICULAR LYMPHOMA (FL) SHOWING A DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) COMPONENT HAVE AN INTERMEDIATE OUTCOME BETWEEN FL AND DLBCL | Laura Magnano Randi | Received |
688-P | DISTINCT INCREASING TREND AND BIRTH-COHORT EFFECT OF FOLLICULAR LYMPHOMA INCIDENCE IN TAIWAN: EPIDEMIOLOGICAL ANALYSES AND IMPLICATIONS | Shang-Ju Wu | Received |
689-P | LONG-TERM OUTCOMES OF 131I-RITUXIMAB RADIOIMMUNOTHERAPY IN FOLLICULAR NON-HODGKIN LYMPHOMA: TEN YEAR UPDATE ON TOXICITY, TIME-TO-NEXT-TREATMENT AND SURVIVIAL OF THE PHASE II INITIAL STUDY | Murali Kesavan | Received |
690-P | LONG TERM OUTCOMES IN PRIMARY OCULAR ADNEXAL MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMAS (POAML): A LARGE SINGLE INSTITUTE COHORT STUDY. | Amrita Desai | Received |
691-P | EARLY TRANSFORMATION IN LOW-GRADE LYMPHOMAS AND ITS ADVERSE PROGNOSTIC SIGNIFICANCE ON SURVIVAL | Luis Miguel Juárez | Received |
692-P | OFATUMOMAB FOR THE TREATMENT OF EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF THE MUCOSA-ASSOCIATED LYMPHOID TISSUE (MALT LYMPHOMA): THE O-MA1 STUDY | Barbara Kiesewetter | Received |
694-P | FINAL RESULTS OF IHC ANALYSIS AND PROGNOSTIC FACTORS IN POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS AFTER SOLID ORGAN TRANSPLANTATION | Manali Kamdar Juárez | Received |
695-P | IMPROVED OUTCOMES WITH HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA WITH PRESERVATION OF COGNITIVE FUNCTION | Shireen Kassam Juárez | Received |
697-P | NONPEGHYLATED LIPOSOMAL DOXORUBICIN AS A COMPONENT OF R-CHOP IS EFFECTIVE AND SAFE IN THE TREATMENT OF A CARDIAC HIGH-RISK AND ELDERLY LYMPHOMA PATIENTS | Luigi Rigacci Juárez | Received |
698-P | METHYLATION OF CELL-FREE CIRCULATING DNA IN PLASMA PREDICTS POOR OUTCOME IN DIFFUSE LARGE B-CELL LYMPHOMA | Lasse Sommer | Received |
701-P | DIFFUSE LARGE B-CELL LYMPHOMA IN THE RITUXIMAB ERA: REAL LIFE ANALYSIS OF PATIENTS WITH REFRACTORY DISEASE OR RELAPSE | Bente Arboe Kristensen | Received |
702-P | CENTRAL NERVOUS SYSTEM INTERNATIONAL PROGNOSTIC INDEX IN DIFFUSE LARGE B-CELL LYMPHOMA | Naoto Tomita Kristensen | Received |
704-P | DETECTION OF BONE MARROW INVOLVEMENT OF DLBCL - COMPARISON OF PET-CT AND BONE MARROW BIOPSY | Yuki Nakajima | Received |
707-P | A NOVEL QUANTITATIVE PCR APPROACH TARGETING INSERTION/DELETION POLYMORPHISMS (INDEL-PCR) FOR CHIMERISM QUANTIFICATION: FINALLY HIGH SENSITIVITY AND QUANTIFICATION CAPACITY TOGETHER | Almudena Navarro-Bailón Kristensen | Received |
708-P | A NEW APPROACH OF DUAL-SCT WITH UNMANIPULATED HAPLO-IDENTICAL GRAFT AND UNRELATED CORD BLOOD IN PATIENTS WITH HEMATOLOGICAL DISORDERS | Depei Wu Kristensen | Received |
709-P | RECIPIENT CCR5 GENETIC VARIATION PREDICTS TRANSPLANT OUTCOMES AFTER HLA-MATCHED UNRELATED DONOR BONE MARROW TRANSPLANTATION. | Tomohiro Horio Kristensen | Received |
710-P | PRESUMABLY FALSE POSITIVE MINIMAL RESIDUAL DISEASE (MRD) QPCR RESULTS AFTER ALLOGENEIC SCT UNCOVERED BY NEXT GENERATION SEQUENCING (NGS) | Michaela Kotrová Kristensen | Received |
711-P | PRE-EMPTIVE THERAPY WITH IFN-?-2B FOR ACUTE LEUKEMIA PATIENTS WITH HIGH RISK OF RELAPSING TENDENCY POST ALLO-HSCT | Depei Wu Kristensen | Received |
712-P | A STUDY OF RHTPO IN COMBINATION WITH CHEMOTHERAPY AND G-CSF FOR PERIPHERAL BLOOD PROGENITOR CELL MOBILIZATION IN PATIENTS WITH RELAPSED NON-HODGKIN LYMPHOMA | Haitao Bai Kristensen | Received |
713-P | A POLYCLONAL POPULATION OF PIGA MUTANT CD52 AND GPI-ANCHOR NEGATIVE T-CELLS CAN GIVE EARLY IMMUNE PROTECTION AFTER ALEMTUZUMAB-BASED T-CELL DEPLETED ALLOGENEIC STEM CELL TRANSPLANTATION | Inge JEDEMA Kristensen | Received |
714-P | WHICH CONDITIONING REGIMEN IS MORE EFFECTIVE FOR HIGH-RISK PATIENTS WITH AML/MDS : COMPARING LOW-DOSE DECITABINE COMBINED WITH MODIFIED BUCY WITH MODIFIED BUCY FOLLOWED BY ALLO-HSCT | Depei Wu Kristensen | Received |
715-P | ELEVATED EXPRESSION OF TIM-3 ON CD8 T CELLS CORRELATES WITH CYTOMEGALOVIRUS REACTIVATION AFTER ALLOGENIC STEM CELL TRANSPLANTATION | Depei Wu Kristensen | Received |
716-P | INTERFERON-GAMMA GENE POLYMORPHISM ASSOCIATE WITH MORTALITY AND GRAFT-VERSUS-HOST DISEASE SEVERITY IN HLA-MATCHED SIBLING BONE MARROW TRANSPLANTATION | Maria Virginia | Received |
718-P | BASELINE LABORATORY VARIABLES SERVE AS POTENT PREDICTORS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RELATED MORTALITY | Roni SHOUVAL | Received |
720-P | COMPARING TIME-DEPENDENT PREDICTIVE PERFORMANCE OF ALLOGENEIC HSCT RISK SCORING SYSTEMS | Joshua Fein Palau | Received |
721-P | PROPHYLACTIC DLI VS NO DLI FOR REFRACTORY ACUTE LEUKEMIA UNDERGOING ALLO-HSCT WITH SEQUENTIAL INTENSIFIED CONDITIONING | Qifa Liu Palau | Received |
722-P | THE PRE-TRANSPLANT BIOMARKER RISK INDEX BASED ON SERUM FERRITIN, ALBUMIN AND CRP CAN PREDICT OUTCOMES INDEPENDENTLY OF THE HCT-CI AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | Tatsuya Suwabe Palau | Received |
723-P | HAPLOIDENTICAL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH ACQUIRED SEVERE APLASTIC ANEMIA | Shuning Zuo Palau | Received |
725-P | MINIMAL RESIDUAL DISEASE AND GRAFT-VERSUS-HOST DISEASE GUIDED SEQUENTIAL CHEMOTHERAPY PLUS DONOR LYMPHOCYTE INFUSION COULD IMPROVE SURVIVAL OF PATIENTS WITH ACUTE LEUKEMIA WHO RELAPSED AFTER ALLO-HSCT | Chen Hua Yan | Received |
727-P | BIFURCATION INTO HEMATOPOIETIC STEM CELL TYPES IS DEPENDENT UPON THE DEVELOPMENTAL SIGNALING MOLECULES | Mihaela CRISAN Palau | Received |
728-P | LACK OF MIR-127 DOWN-REGULATION IN THE TRANSITION FROM HEMATOPOIETIC STEM CELLS TO MULTI-POTENT PROGENITORS LEADS TO PANCYTOPENIA AND DEFECTIVE SELF-RENEWAL | Francesca Ficara Palau | Received |
729-P | NAMPT-NAD+-SIRT2 PATHWAY-TRIGGERED DEACETYLATION OF LMO2 PROTEIN IS INDISPENSABLE IN THE EARLY HEMATOPOIESIS THROUGH COMPLETE TAL1 COMPLEX FORMATION | Tatsuya Morishima | Received |
731-P | EXPRESSION OF BCL2, BUT NOT STAT5 SIGNALING, RESCUES LYMPHOPOIESIS IN THE ABSENCE OF HHEX | Jacob T | Received |
732-P | ANAMORSIN IS ESSENTIAL FOR B-CELL TERMINAL DIFFERENTIATION | Yuri Hamanaka | Received |
733-P | DOWNREGULATION OF CD44 FUNCTIONALLY DEFINES HUMAN T-CELL COMMITMENT | Kirsten Canté-Barrett | Received |
734-P | KNOCKDOWN OF THE ADHESION G-PROTEIN COUPLED RECEPTOR 56 IMPAIRS HUMAN CORD BLOOD STEM AND PROGENITOR CELL FUNCTION | Lixiazi He Palau | Received |
735-P | DISSECTING THE ROLE OF THE MICROENVIRONMENT IN APLASTIC ANEMIA USING AN IN VIVO HAEMATOPOIETIC STEM CELL NICHE MODEL | Ilaria Marina Michelozzi | Received |
737-P | EFFICIENT GENOME EDITING OF MOUSE HEMATOPOIETIC CELLS USING CRISPR/CAS9 TECHNOLOGY | Evgenia Sarrou | Received |
738-P | COMPREHENSIVE PROTEOMIC ANALYSIS OF HUMAN ERYTHROPOIESIS | Emilie-Fleur GAUTIER | Received |
740-P | STAPHYLOCOCCUS AUREUS PROTEIN ISDH INHIBITS THE CD163 PATHWAY FOR HAPTOGLOBIN-FACILITATED HEMOGLOBIN SCAVENGING | Kirstine Lindhardt Madsen | Received |
742-P | AG-519 IS A POTENT ACTIVATOR OF MUTANT PYRUVATE KINASE ASSOCIATED WITH HEMOLYTIC ANEMIA | Charles Kung Madsen | Received |
743-P | REDPLEX: A TARGETED NEXT GENERATION SEQUENCING-BASED DIAGNOSIS FOR PATIENTS WITH HEREDITARY HEMOLYTIC ANEMIAS | Roberta Russo Madsen | Received |
745-P | ELEVATED PLASMA ASYMMETRIC DIMETHYLARGININE LEVELS IN CHILDREN WITH BETA-THALASSEMIA MAJOR MAY BE AN EARLY MARKER FOR ENDOTHELIAL DYSFUNCTION | Orhan GURSEL Madsen | Received |
747-P | PAROXYSMAL NOCTURNAL HEMOGLOBINURIA SCREENING PRACTICE FROM UK CENTRES: A REPORT FROM THE UK PNH NETWORK | Morag griffin Michelozzi | Received |
748-P | DIAGNOSTIC VALUES FOR IRON DEFICIENCY ANEMIA IN CHILDREN AND WOMEN USING SERUM HEPCIDIN AND ZINC PROTOPORPHYRIN (ZPP) | Giridhar Kanuri Madsen | Received |
749-P | UTILITY OF RED CELL INDICES TO DIAGNOSE IRON DEFICIENCY IN RURAL INDIAN CHILDREN | Swaratika majumdar Madsen | Received |
751-P | SEARCH AND YOU SHALL FIND – VARIANT HEMOCHROMATOSIS GENE MUTATIONS AS A CAUSE OF HYPERFERRITINEMIA IN BLOOD DONORS | Adam Høgsbro | Received |
752-P | A PHASE 1, SINGLE AND MULTIPLE ASCENDING DOSE STUDY OF SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AG-519, AN ALLOSTERIC ACTIVATOR OF PYRUVATE KINASE-R IN HEALTHY SUBJECTS | Ann Barbier | Received |
753-P | ANALYSIS OF MOLECULAR MECHANISMS OF DOMINANT-INTERFERING FAS MUTATIONS | Daniel Schäfer Laursen | Received |
754-P | UNSMAKING PRIMARY IMMUNE DEFICIENCIES IN EARLY-ONSET EVANS SYNDROME USING IMMUNOPHENOTYPING AND NGS: TOWARDS A CLINICAL AND GENETIC CLASSIFICATION | Nathalie Aladjidi Laursen | Received |
755-P | MRI SKELETAL MANIFESTATIONS IN GAUCHER DISEASE: UTILITY OF SPANISH-MRI (S-MRI) SCORE AT DIAGNOSIS AND FOLLOW-UP | Marcio Andrade-Campos Laursen | Received |
756-P | SEVUPARIN DEMONSTRATES BINDING TO KEY ADHESION RECEPTORS INVOLVED IN PATHOGENESIS OF SICKLE CELL DISEASE | Maria Lindgren Laursen | Received |
757-P | GLUTATHIONE S TRANSFERASE GENE POLYMORPHISMS AND THE RISK OF CNS COMPLICATIONS OF SICKLE CELL DISEASE IN EGYPTIAN PATIENTS | Hend Ellithy Michelozzi | Received |
760-P | INCREASED LEVELS OF CIRCULATING IMMATURE GRANULOCYTES IN SEPSIS HAVE A SIGNIFICANT IMPACT ON SURVIVAL: RESULTS OF THE FRENCH MULTICENTRIC SEPTIFLUX 2 STUDY | Estelle GUERIN Laursen | Received |
761-P | USEFULNESS OF A THIRTY ONE-GENE PANEL BY NEXT-GENERATION SEQUENCING FOR THE MOLECULAR DIAGNOSTIC OF INHERITED BLEEDING COAGULATION DISORDERS | Jose Maria BASTIDA | Received |
762-P | APPLICATION OF A MOLECULAR DIAGNOSTIC ALGORITHM FOR HEMOPHILIA A AND B USING NEXT-GENERATION SEQUENCING OF THE WHOLE F8, F9 AND VWF GENES. | Bastida Jose | Received |
763-P | ASSAY DISCREPANCY IN MILD HAEMOPHILIA A PATIENTS WITH MUTATIONS IN FVIII A DOMAIN | Alenka Trampuš Bakija | Received |
764-P | ARTHROPATHY IN PATIENTS WITH MODERATE AND SEVERE VON WILLEBRAND DISEASE | Karin van Galen | Received |
765-P | A COMPREHENSIVE NEXT GENERATION SEQUENCING TEST FOR THE DIAGNOSIS OF INHERITED BLEEDING, THROMBOTIC AND PLATELET DISORDERS | Suthesh Sivapalaratnam Galen | Received |
766-P | THE ROLE OF CD72 IN THE REGULATION OF B CELL ACTIVATION THROUGH CD40 IN PRIMARY IMMUNE THROMBOCYTOPENIA | Mingen Lyu | Received |
768-P | QUALITATIVE AND QUANTITATIVE ANALYSIS OF INTRAHEPATIC BLOOD FLOW CHANGES IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT) | Roland Schelker BASTIDA | Received |
771-P | RECOMBINANT THROMBOMODULIN AMELIORATES HEMATOLOGICAL MALIGNANCY-INDUCED DISSEMINATED INTRAVASCULAR COAGULATION MORE PROMPTLY THAN CONVENTIONAL THERAPY WITHOUT CAUSING SEVERE HEMORRHAGIC EVENTS | Naoki Kurita Galen | Received |
772-P | EXTRACELLULAR HISTONES ENHANCE FACTOR XA MEDIATED PROTHROMBIN ACTIVATION WITHOUT PHOSPHOLIPID REQUIREMENT | Yasmina Sahraoui Galen | Received |
773-P | PHORBOL 12-MYRISTATE-13-ACETATE INDUCES VON WILLEBRAND FACTOR PROPEPTIDE RELEASE FROM ENDOTHELIAL CELLS FROM 2 DISTINCT COMPARTMENTS | Ruben Bierings Galen | Received |
774-P | NEWLY DIAGNOSED PLASMA CELL DYSCRASIAS ARE ASSOCIATED WITH ENHANCED TF PATHWAY ACTIVATION, THROMBIN GENERATION AND INCREASED CONCENTRATION OF PROCOAGULANT MICROPARTICLES | Despoina Fotiou BASTIDA | Received |
775-P | ROLE OF ROTATIONAL THROMBELASTOMETRY (ROTEM®) IN RAPID ESTIMATION OF RIVAROXABAN DRUG LEVEL | Hun Chuah Galen | Received |
778-P | INCIDENCE OF PERIPHERAL CIRCULATING CELLS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PHENOTYPE A FIRST EPISODE OF CEREBRAL SINUS VEIN THROMBOSIS: RESULTS FROM A PROSPECTIVE MULTICENTER STUDY | Mariasanta Napolitano | Received |
779-P | REGULATION OF WEIBEL-PALADE BODY EXOCYTOSIS FROM ENDOTHELIAL CELLS BY SYNTAXIN-3 AND STXBP5 CONTAINING SNARE COMPLEXES. | Ruben Bierings | Received |
780-P | COMPARISON OF QUALITY OF LIFE BETWEEN LONG-TERM SURVIVORS OF INDOLENT AND AGGRESSIVE LYMPHOMA: RESULTS OF A SINGLE CENTER PROSPECTIVE COHORT STUDY | Seok Jin Kim | Received |
781-P | IMPACT OF IRON DEFICIENCY ON QUALITY OF LIFE AND WORK CAPACITY OF WOMEN | Lucilia Caramelo Kim | Received |
782-P | IRON DEFICIENCY: UNDERSTANDING PERCEPTIONS OF SUFFERERS AND THE GENERAL PUBLIC | Lucilia Caramelo Kim | Received |
784-P | THE RELATIVE BURDEN OF AL AMYLOIDOSIS ON HEALTH-RELATED QUALITY OF LIFE | Kristen L. McCausland | Received |
785-P | OUTCOME OF PATIENTS WITH RELAPSED/REFRACTORY LYMPHOMA IN A LARGE COHORT INSIDE A PHASE 1 CLINIC DEPARTMENT. | Jean-Marie Michot McCausland | Received |
787-P | HEALTH-RELATED QUALITY OF LIFE ASSESSMENT IN LONGITUDINAL STUDIES INCLUDING MULTIPLE MYELOMA PATIENTS: A CRITICAL REVIEW OF INTERPRETING CHANGES OF SCORES OBTAINED BY EORTC QLQ-C30 | Lene Kongsgaard Nielsen | Received |
2239-LB | Giovanni Cazzaniga | Received | |
2242-LB | David Britton | Received | |
2244-LB | Claudio Cerchione | Received | |
2249-LB | Jeffrey Johnston | Received | |
2251-LB | Rainer Hubmann | Received | |
2253-LB | K. Byrgazov | Received | |
2255-LB | Giovanni Caocci | Received | |
2258-LB | Claudio Cerchione | Received | |
2264-LB | Monika Klimkowska | Received | |
2266-LB | Yohei Kanamori | Received | |
2268-LB | S. Ekwattanakit | Received | |
June 9th - June 12th 2016 Copenhagen
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. |
||||
|